Trial · NCT01769196
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival | Simtuzumab | 12.6 | 95% Confidence Interval 11.3 to 14.4 | months | |
| Progression Free Survival | Simtuzumab Placebo | 15.4 | 95% Confidence Interval 12.6 to 19.1 | months | |
| PFS Among the Participants With sLOXL2 ≥ 50th Percentile | Simtuzumab | 11.7 | 95% Confidence Interval 9.9 to 15.9 | months | |
| PFS Among the Participants With sLOXL2 ≥ 50th Percentile | Simtuzumab Placebo | 14.3 | 95% Confidence Interval 10.4 to 19.1 | months | |
| PFS Among the Participants With sLOXL2 ≥ 75th Percentile | Simtuzumab | 11.6 | 95% Confidence Interval 9.0 to 15.0 | months | |
| PFS Among the Participants With sLOXL2 ≥ 75th Percentile | Simtuzumab Placebo | 16.9 | 95% Confidence Interval 7.7 to 21.7 | months | |
| Overall Survival (OS) | Simtuzumab | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Simtuzumab Placebo | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival Among the Participants With sLOXL2 ≥ 50th Percentile | Simtuzumab | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival Among the Participants With sLOXL2 ≥ 50th Percentile | Simtuzumab Placebo | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival Among the Participants With sLOXL2 ≥ 75th Percentile | Simtuzumab | NA | 95% Confidence Interval 19.2 to NA | months | |
| Overall Survival Among the Participants With sLOXL2 ≥ 75th Percentile | Simtuzumab Placebo | NA | 95% Confidence Interval NA to NA | months | |
| Relative Change From Baseline in FVC % Predicted | Simtuzumab | Week 54 | -9.20 | Standard Error 0.643 | Percent change in FVC % predicted |
| Relative Change From Baseline in FVC % Predicted | Simtuzumab Placebo | Week 54 | -8.88 | Standard Error 0.658 | Percent change in FVC % predicted |
| Relative Change From Baseline in FVC % Predicted | Simtuzumab | Week 106 | -13.70 | Standard Error 0.883 | Percent change in FVC % predicted |
| Relative Change From Baseline in FVC % Predicted | Simtuzumab Placebo | Week 106 | -12.16 | Standard Error 0.908 | Percent change in FVC % predicted |
| Relative Change From Baseline in FVC % Predicted | Simtuzumab | Week 130 | -18.09 | Standard Error 1.712 | Percent change in FVC % predicted |
| Relative Change From Baseline in FVC % Predicted | Simtuzumab Placebo | Week 130 | -11.83 | Standard Error 1.600 | Percent change in FVC % predicted |
| Definite Acute Exacerbations of IPF Among Adjudicated Respiratory Hospitalizations | Simtuzumab | 5 | Participants | ||
| Definite Acute Exacerbations of IPF Among Adjudicated Respiratory Hospitalizations | Simtuzumab Placebo | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01769196/results